Department of Biotechnology and Bioinformatics, School of Life Sciences, University of Hyderabad, Hyderabad, Telangana, India.
J Biomol Struct Dyn. 2022 Apr;40(7):2917-2933. doi: 10.1080/07391102.2020.1844060. Epub 2020 Nov 9.
COVID-19, caused by SARS-CoV-2, is severe respiratory illnesses leading to millions of deaths worldwide in very short span. The high case fatality rate and the lack of medical counter measures emphasize for an urgent quest to develop safe and effective vaccine. Receptor-binding domain (RBD) of spike protein of SARS-CoV-2 binds to the ACE2 receptor on human host cell for the viral attachment and entry, hence considered as a key target to develop vaccines, antibodies and therapeutics. In this study, immunoinformatics approach was employed to design a novel multi-epitope vaccine using RBD of SARS-CoV-2 spike protein. The potential B- and T-cell epitopes were selected from RBD sequence using various bioinformatics tools to design the vaccine construct. The designed multi-epitope vaccine encompasses 146 amino acids with an adjuvant (human beta-defensin-2), which was further computationally evaluated for several parameters including antigenicity, allergenicity and stability. Subsequently, three-dimensional structure of vaccine construct was modelled and then docked with various toll-like receptors. Molecular dynamics (MD) study of docked TLR3-vaccine complex delineated it to be highly stable during simulation time and the stabilization of interaction was majorly contributed by electrostatic energy. The docked complex also showed low deformation and increased rigidity in motion of residues during dynamics. Furthermore, cloning of the multi-epitope vaccine was carried out to generate the plasmid construct for expression in a bacterial system. Altogether, our study suggests that the designed vaccine candidate containing RBD region could provide the specific humoral and cell-mediated immune responses against SARS-CoV-2.Communicated by Ramaswamy H. Sarma.
新型冠状病毒病(COVID-19)由严重急性呼吸系统综合征冠状病毒 2(SARS-CoV-2)引起,是一种严重的呼吸道疾病,在很短的时间内导致了全世界数百万人死亡。高病死率和缺乏医疗对策强调迫切需要开发安全有效的疫苗。SARS-CoV-2 刺突蛋白的受体结合域(RBD)与人宿主细胞上的 ACE2 受体结合,用于病毒附着和进入,因此被认为是开发疫苗、抗体和治疗药物的关键靶标。在这项研究中,使用 SARS-CoV-2 刺突蛋白的 RBD 采用免疫信息学方法设计了一种新型多表位疫苗。使用各种生物信息学工具从 RBD 序列中选择潜在的 B 细胞和 T 细胞表位来设计疫苗构建体。设计的多表位疫苗包含 146 个氨基酸和一种佐剂(人β防御素-2),进一步对其进行了抗原性、过敏性和稳定性等几个参数的计算评估。随后,对疫苗构建体的三维结构进行建模,然后与各种 Toll 样受体对接。对接的 TLR3-疫苗复合物的分子动力学(MD)研究表明,在模拟过程中它非常稳定,相互作用的稳定主要由静电能贡献。对接复合物在运动过程中还表现出低变形和增加的残基刚性。此外,还进行了多表位疫苗的克隆,以生成用于在细菌系统中表达的质粒构建体。总之,我们的研究表明,含有 RBD 区域的设计疫苗候选物可以针对 SARS-CoV-2 提供特异性的体液和细胞介导的免疫反应。